PRESS RELEASE FROM SINO BIOLOGICAL INC.

Sino Biological Partners with Nanommune Inc. to Develop and Market a Novel Coronavirus Multiplex Serological Assay

Posted Apr 17, 2020

Sino Biological Partners with Nanommune Inc. to Develop and Market a Novel Coronavirus Multiplex Serological Assay

 

April 17, 2020; Wayne, PA

Sino Biological, Inc. today announced a co-development agreement with Nanommune Inc., an Irvine, California based biotechnology company specializing in the development and application of multiplex array technology. Under the terms of the agreement, the two companies will jointly develop coronavirus antigen array products for serological studies of COVID-19 and other infectious diseases. The two companies also debuted the first product this week under Sino Biological’s new brand SinommuneTM. This new product features 65 viral antigens from six major groups of the viral superfamily that can lead to respiratory infections, including coronavirus (SARS-COV-2 and others), PIV, RSV, MPV, adenovirus, and influenza. The array will be used for serosurveillance studies of the aforementioned viruses in affected populations.

“We’re very excited about this strategic alliance. This collaboration is built upon the companies’ shared interest in fighting infectious disease, a task that seems more important now than ever,” Sino Biological CEO Dr. Jie Zhang stated. “The collaboration allows us to make our recombinant coronavirus antigens available on a microarray multiplex-based platform, which enables rapid profiling of antibodies interacting with these targets in biological samples. I believe this will be a very useful resource for vaccine development and epidemiological studies.”

In a recent joint study published on bioRxiv, researchers from University of California, Irvine (UCI), Cerus Corporation, University of Maryland, Oregon Health and Science University, and the Vitalant Research Institute used this array to characterize the antibody profile of convalescent blood specimens from eight PCR-confirmed COVID-19 patients and in 144 negative control sera collected prior to the pandemic. The results demonstrated a distinct antibody profile for SARS-COV-2 only in confirmed COVID-19 patients. In comparison, both groups showed comparable reactivity towards antigens from common cold coronavirus and other virus types. This study highlights the potential of this array as a serosurveillance tool in epidemiological studies of COVID-19. The array can also aid in studies to correlate antibody responses with clinical outcomes.

“We are extremely pleased with the performance of the Sinommune array product and believe this platform will serve as a foundational tool for serological studies in the global fight against COVID-19,” said Dr. Philip Felgner, Director of the Vaccine R&C Center at UCI Medical School. “In order for communities around the globe to understand the prevalence and threat posed by COVID-19, a comprehensive serosurveillance program is necessary to provide policy makers, researchers, and front-line medical professionals with the data necessary to forecast and respond to this fast-moving and dynamic threat.”

 

About Sino Biological

Sino Biological is an international reagent supplier and service provider. The company specializes in recombinant antigen production and antibody development. The company’s ever-growing portfolio of products includes recombinant proteins, monoclonal antibodies, ELISA kits, expression clones, cell culture media, and other molecular biology tools. The company also offers a variety of customized services with a primaryfocus on recombinant production of antigens and antibodies. Sino Biological is dedicated to virology and infectious disease research. Its newly launched ProVirTM collection is the world’s largest viral antigen bank, carrying over 800 products from 350 strains of viruses. More information can be found by visiting www.sinobiological.com.

About Nanommune

Nanommune Inc. is a biotechnology company focused on the development of cutting-edge tools for the medical and research communities. Nanommune’s high-throughput proteomic antigen-specific microarray platform revolutionizes diagnostic, serosurveillance, and vaccine research by offering medical, research, and public health experts with fast, highly accurate, and rapidly deployable suite to tools to accomplish the extremely important needs facing the global health community. The company’s pathogen-specific microarrays can be deployed rapidly at scale and serve as a much needed-tool in the fight against emerging infectious diseases. In addition to the microarray platform, Nanommune offers qPCR testing kits as well as proprietary vaccine discovery kits to aid in the fight against emerging infectious disease around the world. More information can be found by visiting www.nanommuneinc.com.

 

Forward-Looking Statements

Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors. Sino Biological assumes no obligation to update these forward-looking statements and does not intend to do so.

 

Contact Info:

Sino Biological, Inc.

Phone: +1-832-992-9086

Email: [email protected]

Website: www.sinobiological.com

 

Nanommune, Inc.

Phone: +1-949-637-9466

Email: [email protected]

Website: www.nanommuneinc.com